Overcoming Barriers to Intravesical Gemcitabine System in High-Risk NMIBC

As bladder-sparing therapies like a gemcitabine intravesical system (Inlexzo; formerly TAR-200) emerge for high-risk non–muscle-invasive bladder cancer (NMIBC), ensuring equitable patient access requires overcoming distinct logistical and administrative challenges. Beyond clinical candidate selection, health systems must navigate regional care delivery constraints and reimbursement dynamics.

In an interview with CancerNetwork®, Goutham Vemana, MD, chair of the Department of Urology at Allegheny Health Network (AHN) in Pittsburgh, PA, suggested geographical barriers can be mitigated by distributing treatment capabilities across regional office networks. While specific payer requirements may restrict where advanced intravesical therapies can be administered within a health system, real-world experience demonstrates surprisingly manageable reimbursement hurdles.

Furthermore, concerns surrounding financial toxicity can be proactively addressed. Vemana noted that industry-backed patient assistance programs and independent foundations offer robust support mechanisms to offset out-of-pocket costs. By pairing regional site access with dedicated financial navigation, multidisciplinary teams can streamline care delivery and help patients access novel, bladder-sparing innovations.

Transcript:

Some of the barriers are logistical for patients. We see a lot of patients across western Pennsylvania, and fortunately, for a large system like ours, we have multiple office sites throughout the region that can offer these treatments, which helps. There are some nuances with insurance and coverage and where treatments can be administered. in a network like ours, there are certain places where we are allowed to administer these treatments, which does restrict us somewhat. Some private practice urology groups are doing this in their offices without too much difficulty. Insurance coverage is always a concern, but many groups have not experienced too many problems. When I have talked to urology colleagues at national meetings who have started these treatments, they have not found too many barriers to reimbursement. For patients with limited finances, there are many foundations that companies like Johnson & Johnson work with, along with patients, to help minimize the financial toxicity of these treatments.